KMPHARMACEUTICAL decides 16.3% dilutive rights offering to CEO to raise 1 billion won for operating funds

KMPHARMACEUTICAL resolved on July 14, 2026 to conduct a third-party allotment rights offering to CEO Baek Seung-won.
The company will issue 908,265 new shares at 1,101 KRW per share to raise approximately 1 billion KRW for operating funds, resulting in a 16.3% dilution of existing shares.
The issuance price is at a 10% discount to the reference price of 1,223 KRW, and the new shares are subject to a 1-year lock-up restriction.
[AI Summary]This rights offering involves severe dilution of 16.3% to a related party CEO, undermining existing shareholder value. The proceeds are for routine operating expenses rather than high-growth investments, and the insider nature raises governance concerns. Downward pressure on the stock price is expected, requiring investor caution.